Schizophrenia Schizoaffective Clinical Trial
Official title:
Clozapine CHAMPION-ECHO (Center for Help and Assistance for Maryland Prescribers- Improving Outcomes Network Using Extension for Community Healthcare Outcomes); Randomized Educational Study to Improve Clozapine Prescribing Through a Project ECHO Model
In a randomized controlled design with approximately 26 biweekly sessions over 12 months, the investigators propose to test the effectiveness of an ECHO-based intervention for improving the use of clozapine in people eligible for clozapine. The sessions will include: 1) active dissemination of knowledge and information by an expert "hub" followed by 2) clozapine case presentations and vignettes submitted by the "spokes". This intervention, Clozapine CHAMPION-ECHO (Center for Help and Assistance for Maryland Prescribers- Improving Outcomes Network using Extension for Community Healthcare Outcomes, will be referred to as "CHAMPION" throughout.. To minimize ANC monitoring barriers and maximize recruitment, the investigators will provide Food and Drug Administration (FDA)-cleared ANC point of care (POC) monitoring devices to all study sites, including those in the control condition. The investigators will enroll at least 300 prescribers and additional clinical team members (up to 300) from 60 outpatient mental health clinics (OMHCs) and other treatment sites; approximately half the OHMCs will be randomized to CHAMPION and half randomized to enhanced treatment as usual (ETAU).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414058 -
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes
|
Phase 2 | |
Not yet recruiting |
NCT03461432 -
Personalised Cognitive Remediation Therapy (pCRT)
|
N/A | |
Recruiting |
NCT05660018 -
TMS Related Biomarker Assessments
|
N/A | |
Not yet recruiting |
NCT06275451 -
Qualitative Study of Emotional Regulation in Schizophrenia
|
||
Completed |
NCT04567524 -
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
|
Phase 2 | |
Recruiting |
NCT05643196 -
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia
|
Phase 2 |